vs
Side-by-side financial comparison of Fortive (FTV) and MESA LABORATORIES INC (MLAB). Click either name above to swap in a different company.
Fortive is the larger business by last-quarter revenue ($139.0M vs $65.1M, roughly 2.1× MESA LABORATORIES INC). Fortive runs the higher net margin — 133.6% vs 5.6%, a 128.0% gap on every dollar of revenue. On growth, MESA LABORATORIES INC posted the faster year-over-year revenue change (3.6% vs -91.4%). Fortive produced more free cash flow last quarter ($335.5M vs $18.0M). Over the past eight quarters, MESA LABORATORIES INC's revenue compounded faster (5.1% CAGR vs -69.8%).
Fortive Corporation is an American industrial technology conglomerate company headquartered in Everett, Washington. The company specializes in providing essential technologies for connected workflow solutions; designing, developing, manufacturing and distributing professional and engineered products, software and services. Their products and services are split into three strategic segments; Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. As of Decem...
Mesa Laboratories Inc. develops, manufactures and sells professional quality control, calibration and monitoring instruments as well as related supporting services. Its core offerings cater to healthcare, pharmaceutical, food and beverage, industrial hygiene and environmental testing markets, helping global clients meet regulatory compliance and operational safety requirements.
FTV vs MLAB — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $139.0M | $65.1M |
| Net Profit | $185.7M | $3.6M |
| Gross Margin | — | 64.2% |
| Operating Margin | 75.4% | 12.2% |
| Net Margin | 133.6% | 5.6% |
| Revenue YoY | -91.4% | 3.6% |
| Net Profit YoY | -11.1% | 316.6% |
| EPS (diluted) | $0.58 | $0.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.0M | $65.1M | ||
| Q3 25 | $1.0B | $60.7M | ||
| Q2 25 | $1.5B | $59.5M | ||
| Q1 25 | $1.5B | $62.1M | ||
| Q4 24 | $1.6B | $62.8M | ||
| Q3 24 | $1.5B | $57.8M | ||
| Q2 24 | $1.6B | $58.2M | ||
| Q1 24 | $1.5B | $58.9M |
| Q4 25 | $185.7M | $3.6M | ||
| Q3 25 | $55.0M | $2.5M | ||
| Q2 25 | $166.6M | $4.7M | ||
| Q1 25 | $171.9M | $-7.1M | ||
| Q4 24 | $208.8M | $-1.7M | ||
| Q3 24 | $221.6M | $3.4M | ||
| Q2 24 | $195.1M | $3.4M | ||
| Q1 24 | $207.4M | $-254.6M |
| Q4 25 | — | 64.2% | ||
| Q3 25 | 63.2% | 61.5% | ||
| Q2 25 | 59.0% | 62.0% | ||
| Q1 25 | 59.8% | 61.8% | ||
| Q4 24 | 60.3% | 63.3% | ||
| Q3 24 | 60.0% | 61.3% | ||
| Q2 24 | 59.8% | 64.0% | ||
| Q1 24 | 59.3% | 62.1% |
| Q4 25 | 75.4% | 12.2% | ||
| Q3 25 | 15.5% | 7.8% | ||
| Q2 25 | 14.6% | 5.1% | ||
| Q1 25 | 15.8% | 2.4% | ||
| Q4 24 | 19.0% | 9.2% | ||
| Q3 24 | 19.3% | 6.1% | ||
| Q2 24 | 19.4% | 9.6% | ||
| Q1 24 | 19.8% | -460.6% |
| Q4 25 | 133.6% | 5.6% | ||
| Q3 25 | 5.4% | 4.1% | ||
| Q2 25 | 11.0% | 8.0% | ||
| Q1 25 | 11.7% | -11.4% | ||
| Q4 24 | 12.9% | -2.7% | ||
| Q3 24 | 14.4% | 5.9% | ||
| Q2 24 | 12.6% | 5.8% | ||
| Q1 24 | 13.6% | -432.2% |
| Q4 25 | $0.58 | $0.65 | ||
| Q3 25 | $0.16 | $0.45 | ||
| Q2 25 | $0.49 | $0.85 | ||
| Q1 25 | $0.50 | $-1.30 | ||
| Q4 24 | $0.60 | $-0.31 | ||
| Q3 24 | $0.63 | $0.63 | ||
| Q2 24 | $0.55 | $0.62 | ||
| Q1 24 | $0.58 | $-47.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $375.5M | $29.0M |
| Total DebtLower is stronger | $3.2B | $68.4M |
| Stockholders' EquityBook value | $6.5B | $186.7M |
| Total Assets | $11.7B | $434.8M |
| Debt / EquityLower = less leverage | 0.50× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $375.5M | $29.0M | ||
| Q3 25 | $430.8M | $20.4M | ||
| Q2 25 | $1.8B | $21.3M | ||
| Q1 25 | $892.1M | $27.3M | ||
| Q4 24 | $813.3M | $27.3M | ||
| Q3 24 | $811.3M | $24.3M | ||
| Q2 24 | $644.1M | $28.5M | ||
| Q1 24 | $704.6M | $28.2M |
| Q4 25 | $3.2B | $68.4M | ||
| Q3 25 | $3.3B | $69.4M | ||
| Q2 25 | $4.8B | $70.3M | ||
| Q1 25 | $3.9B | $71.3M | ||
| Q4 24 | $3.7B | $72.2M | ||
| Q3 24 | $3.9B | $73.1M | ||
| Q2 24 | $3.8B | $74.1M | ||
| Q1 24 | $3.9B | — |
| Q4 25 | $6.5B | $186.7M | ||
| Q3 25 | $6.5B | $178.5M | ||
| Q2 25 | $10.4B | $172.5M | ||
| Q1 25 | $10.2B | $159.8M | ||
| Q4 24 | $10.2B | $155.2M | ||
| Q3 24 | $10.6B | $161.5M | ||
| Q2 24 | $10.5B | $150.7M | ||
| Q1 24 | $10.5B | $145.4M |
| Q4 25 | $11.7B | $434.8M | ||
| Q3 25 | $11.9B | $430.4M | ||
| Q2 25 | $18.2B | $435.7M | ||
| Q1 25 | $17.1B | $433.3M | ||
| Q4 24 | $17.0B | $433.3M | ||
| Q3 24 | $17.5B | $454.1M | ||
| Q2 24 | $17.3B | $440.4M | ||
| Q1 24 | $17.5B | $446.8M |
| Q4 25 | 0.50× | 0.37× | ||
| Q3 25 | 0.51× | 0.39× | ||
| Q2 25 | 0.46× | 0.41× | ||
| Q1 25 | 0.38× | 0.45× | ||
| Q4 24 | 0.36× | 0.47× | ||
| Q3 24 | 0.37× | 0.45× | ||
| Q2 24 | 0.36× | 0.49× | ||
| Q1 24 | 0.38× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $365.9M | $18.8M |
| Free Cash FlowOCF − Capex | $335.5M | $18.0M |
| FCF MarginFCF / Revenue | 241.4% | 27.7% |
| Capex IntensityCapex / Revenue | 21.9% | 1.1% |
| Cash ConversionOCF / Net Profit | 1.97× | 5.17× |
| TTM Free Cash FlowTrailing 4 quarters | $978.1M | $37.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $365.9M | $18.8M | ||
| Q3 25 | $164.4M | $8.2M | ||
| Q2 25 | $311.2M | $1.9M | ||
| Q1 25 | $241.7M | $12.7M | ||
| Q4 24 | $502.2M | $18.1M | ||
| Q3 24 | $459.0M | $5.3M | ||
| Q2 24 | $308.9M | $10.7M | ||
| Q1 24 | $256.7M | $12.9M |
| Q4 25 | $335.5M | $18.0M | ||
| Q3 25 | $153.1M | $7.1M | ||
| Q2 25 | $274.5M | $884.0K | ||
| Q1 25 | $215.0M | $11.9M | ||
| Q4 24 | $465.2M | $17.3M | ||
| Q3 24 | $431.2M | $3.5M | ||
| Q2 24 | $279.7M | $9.9M | ||
| Q1 24 | $230.3M | $12.3M |
| Q4 25 | 241.4% | 27.7% | ||
| Q3 25 | 14.9% | 11.7% | ||
| Q2 25 | 18.1% | 1.5% | ||
| Q1 25 | 14.6% | 19.2% | ||
| Q4 24 | 28.7% | 27.6% | ||
| Q3 24 | 28.1% | 6.0% | ||
| Q2 24 | 18.0% | 16.9% | ||
| Q1 24 | 15.1% | 21.0% |
| Q4 25 | 21.9% | 1.1% | ||
| Q3 25 | 1.1% | 1.8% | ||
| Q2 25 | 2.4% | 1.7% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 2.3% | 1.3% | ||
| Q3 24 | 1.8% | 3.1% | ||
| Q2 24 | 1.9% | 1.5% | ||
| Q1 24 | 1.7% | 0.9% |
| Q4 25 | 1.97× | 5.17× | ||
| Q3 25 | 2.99× | 3.32× | ||
| Q2 25 | 1.87× | 0.40× | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 2.41× | — | ||
| Q3 24 | 2.07× | 1.54× | ||
| Q2 24 | 1.58× | 3.17× | ||
| Q1 24 | 1.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FTV
| Services | $137.9M | 99% |
| Products | $1.1M | 1% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
